Vidan Diagnostics Launches Reagent Application for its β-Hydroxybutyrate 21FS Assay on the Siemens Atellica^® Clinical Chemistry System.

SAN ANTONIO, Texas, August 21, 2020 – Vidan Diagnostics, LLC today announced that its β-Hydroxybutyrate 21FS Next Generation Reagent is now available on the Siemens Atellica^® clinical chemistry system. Beta-Hydroxybutyrate (BHB) is an important marker when used in conjunction with clinical findings and other laboratory tests for the diagnosis and management of ketoacidosis and its main causative factor, diabetic ketoacidosis (DKA).

Siemens Atellica^® Reagent Application for Beta-Hydroxybutyrate
Vidan Diagnostics’ β-Hydroxybutyrate 21FS assay offers 10 weeks calibration and onboard stability and its convenient packaging reduces the amount of effort needed to fill the Atellica^® reagent wells. “We have seen the U.S. market transition from the Siemens Vista™ 500s and 1500s to the Atellica^® in the recent months, therefore we developed and validated the reagent application to meet the market demand”, said Gilbert Mejia, CEO of Vidan Diagnostics. “Our new Atellica^® customers are very satisfied with our performance, packaging and significant cost savings”, Mejia added.

Beta-Hydroxybutyrate
Beta-hydroxybutyrate is the predominate ketone body produced during Diabetic Ketoacidosis, (DKA) It’s relative proportion in the blood, (78%) is greater than the other two ketones, acetoacetate, (20%) and acetone, (2%) and is therefore the best indicator of DKA. DKA is a serious condition that can lead to diabetic coma or even death.

Founded in 2018, Vidan Diagnostics LLC is a supplier of medical diagnostic products. It is focused on medical devices and reagents used for diagnosing and monitoring patients with conditions of diabetes, sepsis, anemia, heart disease and stroke. Vidan Diagnostics is dedicated to delivering proven and innovative products to all people in all places, in all aspects and stages of life with integrity and reliability. The company is headquartered in San Antonio, Texas.